Telix at ASCO 2026

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.

ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (177Lu-rosopatamab tetraxetan) in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

The presentation will be delivered by Pedro Barata, MD, MSc, on Monday, June 1.

Telix’s renal cancer therapeutics program will also be featured at ASCO, with a poster presentation on LUTEON, a Phase 2/3 study evaluating TLX250-Tx (177Lu-girentuximab) in advanced relapsed or recurrent clear cell renal cell carcinoma.

TLX591-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Learn more about the presentations below

Chicago, IL

May 29 – June 2 2026

Abstract presentations 

Presentations
Presentations
Pedro Barata

UH Cleveland
ProstACT Global Phase 3 study (Part 1): Safety and dosimetry of TLX591-Tx (177Lu-rosopatamab tetraxetan) plus standard-of-care in patients with metastatic castration-resistant prostate cancer (NCT06520345)
Oral Presentation

June 1, 3:12 PM – 3:24 PM CDT

Arie Crown Theater

Sumanta Pal

City of Hope Comprehensive Cancer Care
LUTEON Phase 3 study: Safety and efficacy of TLX250-Tx (177Lu-girentuximab) in advanced relapsed or recurrent ccRCC (NCT07197580)
Poster Presentation

May 31, 9:30 AM – 11:30 AM CDT

Hall A (Board 109a)